Loading clinical trials...
Loading clinical trials...
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2)
The purpose of this study is to compare the clinical efficacy of daily vs. 3-day (MWF) buprenorphine/naloxone combination tablet administration and determine whether outcomes are improved when using a 3-day schedule in which all doses are ingested at the clinic vs. one in which take-home doses are given on intervening days.
Mon/Wed/Fri dosing with the 8 mg buprenorphine/naloxone tablet is as safe and effective as daily dosing and is preferred by patients to daily dosing. Multiple doses of the combination tablet (e.g. 16mg, 24mg) are well tolerated by patients. A 3 day schedule with take-outs is as effective as a 3-day schedule in which all medication is ingested at the clinic
Age
18 - 62 years
Sex
ALL
Healthy Volunteers
No
University of Colorado Health Sciences Center
Denver, Colorado, United States
Start Date
June 1, 1997
Primary Completion Date
August 1, 1997
Completion Date
August 1, 1997
Last Updated
May 4, 2017
Heroin Dependence
DRUG
Lead Sponsor
University of Colorado, Denver
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05657106